← Eichor
Condition: Diffuse Hemispheric Glioma H3 G34 Mutant Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Diffuse Hemispheric Glioma H3 G34 Mutant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT069144795G-EMERALD: Amivantamab in Malignant Brain Tumours
Phase 1 · 2 location(s) · Institute of Cancer Research, United Kingdom · NCT06632236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.